CA2366059A1 - Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer - Google Patents

Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer Download PDF

Info

Publication number
CA2366059A1
CA2366059A1 CA002366059A CA2366059A CA2366059A1 CA 2366059 A1 CA2366059 A1 CA 2366059A1 CA 002366059 A CA002366059 A CA 002366059A CA 2366059 A CA2366059 A CA 2366059A CA 2366059 A1 CA2366059 A1 CA 2366059A1
Authority
CA
Canada
Prior art keywords
mage
glu
seq
leu
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002366059A
Other languages
English (en)
Inventor
Alfonso Serrano
Bernard Lethe
Christophe Lurquin
Etienne De Plaen
Donata Rimoldi
Thierry Boon-Falleur
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Ludwig Institute for Cancer Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd filed Critical Ludwig Institute for Cancer Research Ltd
Publication of CA2366059A1 publication Critical patent/CA2366059A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des molécules d'ADN complémentaire isolées et déterminées grâce à une méthode élaborée pour faciliter le niveau d'expression génique. L'invention concerne également des protéines et des peptides obtenus sur la base de ces molécules d'ADN complémentaire, ainsi que différentes utilisations diagnostiques et thérapeutiques de ces matières.
CA002366059A 1999-03-02 2000-03-01 Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer Abandoned CA2366059A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26097899A 1999-03-02 1999-03-02
US09/260,978 1999-03-02
PCT/US2000/005346 WO2000052163A1 (fr) 1999-03-02 2000-03-01 Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer

Publications (1)

Publication Number Publication Date
CA2366059A1 true CA2366059A1 (fr) 2000-09-08

Family

ID=22991462

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002366059A Abandoned CA2366059A1 (fr) 1999-03-02 2000-03-01 Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer

Country Status (7)

Country Link
EP (1) EP1194542A1 (fr)
JP (1) JP2003512814A (fr)
KR (1) KR20020011967A (fr)
AU (1) AU3389500A (fr)
CA (1) CA2366059A1 (fr)
NZ (1) NZ513739A (fr)
WO (1) WO2000052163A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053956A1 (fr) 2005-11-14 2007-05-18 Universite Laval Antigene cancereux mage-a9 et ses utilisations
SG11201913302SA (en) 2017-07-07 2020-01-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers
US10800823B2 (en) 2017-07-07 2020-10-13 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against lung cancer, including NSCLC, SCLC and other cancers
FR3087448B1 (fr) 2018-10-23 2023-10-13 Pdc Line Pharma Lignee pdc modifiee pour secreter une cytokine
TW202039535A (zh) 2018-12-18 2020-11-01 德商英麥提克生物技術股份有限公司 B*08限制肽和肽組合物抗癌免疫治療和相關方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612201A (en) * 1991-05-23 1997-03-18 Ludwig Institute For Cancer Research Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
KR20020011967A (ko) 2002-02-09
AU3389500A (en) 2000-09-21
WO2000052163A1 (fr) 2000-09-08
EP1194542A1 (fr) 2002-04-10
JP2003512814A (ja) 2003-04-08
NZ513739A (en) 2001-09-28

Similar Documents

Publication Publication Date Title
KR100306464B1 (ko) Mhc분자hla-c-클론10과복합체를형성하는분리된펩티드및그것의사용
CN1318447C (zh) 得自亲环蛋白b的肿瘤抗原肽
EP0690675B1 (fr) Acide nucleique codant pour un precurseur d'antigene de rejet de tumeur
Zarour et al. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100
US20120123090A1 (en) Novel tumor antigen protein sart-3 and tumor antigen peptides thereof
US6555652B1 (en) Tumor antigen peptide derivatives
US6605711B1 (en) NY-ESO-1 peptide derivatives, and uses thereof
US6913891B1 (en) Human myeloid terminal differentiation response gene
EP1230261B1 (fr) Derives peptidiques de ny-eso-1 et leurs applications
US20030180739A1 (en) Reagents and methods for identifying gene targets for treating cancer
JP2003000270A (ja) 腫瘍抗原
CA2366059A1 (fr) Clonage d'adn complementaire de 5, 8, 9 et 11 de mage et leur utilisation dans le diagnostic du cancer
CA2386029A1 (fr) P-glycoproteines provenant de <i>macaca fascicularis</i> et utilisations correspondantes
JP4190291B2 (ja) 癌細胞の増殖を調節するのに有用なポリヌクレオチド
US5837476A (en) Methods for determining disorders by assaying for a non-tyrosinase, tumor rejection antigen precursor
CN100393745C (zh) 一种肿瘤抗原蛋白质和肿瘤抗原肽
CA2353102A1 (fr) Nouvelle proteine d'antigene tumoral art-1 et peptide d'antigene tumoral de cette derniere
CA2182969A1 (fr) Procede d'identification des individus atteints d'anomalie cellulaire
CA2319668C (fr) Genes humains tsc403 et ing1l
CA2384981A1 (fr) Glycoproteines p et leurs utilisations
CA2165435C (fr) Nouveaux precurseurs d'antigenes pour le rejet des tumeurs et molecules d'acides nucleiques codant pour ces precurseurs
JP2001245675A (ja) 腫瘍抗原
US7270980B2 (en) Compounds for immunodiagnosis of prostate cancer and methods for their use
CA2300371A1 (fr) Proteine 1(3)mbt, polynucleotide codant pour ladite proteine, son polynucleotide antisense et anticorps reconnaissant ladite proteine
AU2313401A (en) Novel human myeloid terminal differentiation response gene

Legal Events

Date Code Title Description
FZDE Dead